Inion review exceeds expectations with steady results
This article was originally published in Clinica
Biodegradable orthopaedic implants specialist Inion has said the execution of its strategic review plan to improve its financial performances is exceeding expectations, as reflected in E2.3m ($3.2m) sales recorded in the first half of 2007, E300,000 ahead of analysts' expectations.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.